World Scientific
Skip main navigation

Cookies Notification

We use cookies on this site to enhance your user experience. By continuing to browse the site, you consent to the use of our cookies. Learn More
×

System Upgrade on Tue, May 28th, 2024 at 2am (EDT)

Existing users will be able to log into the site and access content. However, E-commerce and registration of new users may not be available for up to 12 hours.
For online purchase, please visit us again. Contact us at customercare@wspc.com for any enquiries.
Handbook of Immunological Properties of Engineered Nanomaterials cover
Also available at Amazon and Kobo

This unique book provides comprehensive overview of the field of immunology related to engineered nanomaterials used for biomedical applications. It contains literature review, case studies and protocols. The book can serve as a source of information about nanoimmunotoxicology for both junior scientists and experts in the field. The authors have more than 10 years of experience with preclinical characterization of engineered nanomaterials used for medical applications, and they share their experience with the readers. In addition, the international team of experts in the field provides the opinion and share the expertise on individual topics related to nanoparticle physicochemical characterization, hematocompatibility, and effects on the immune cell function . The second edition contains updated chapters from the first edition plus new chapters covering areas of tumor immunology, nanoparticle interaction with lymphatic system, mathematical modeling of protein corona, utilization of nanoparticles for the delivery of antiviral drugs, extensive analysis of nanoparticle anti-inflammatory and immunosuppressive properties, novel ways of protecting therapeutic nanoparticles from the immune recognition, as well as case studies regarding nanoparticle sterilization, complement activation, protein binding and immunotherapy of cancer. The second edition comes in 3 volumes. Volume 1 is focused on nanoparticle characterization, sterility and sterilization, pyrogen contamination and depyrigenation. It also contains overview of regulatory guidelines, protocols for in vitro and in vivo immunotoxicity studies, and correlation between in vitro and in vivo immunoassays. Volume 2 is focused on hematocompatibility of nanomaterials. It provides comprehensive review and protocols for investigating nanoparticle interaction with erythrocytes, platelets, endothelial cells, plasma coagulation factors and plasma proteins forming so called "corona" around nanoparticles. Volume 3 is dedicated to nanoparticle interaction with and effects on the immune cell function. It also contains examples of nanoparticle use for delivery of antiviral and anti-inflammatory drugs.

Contents:
  • Volume 1: Key Considerations for Nanoparticle Characterization Prior to Immunotoxicity Studies:
    • Immunological Properties of Engineered Nanomaterials: An Introduction (Marina A Dobrovolskaia and Scott E McNeil)
    • Importance of Physicochemical Characterization Prior to Immunological Studies (Jeffrey D Clogston and Anil K Patri)
    • Nanoparticle Sterility and Sterilization of Nanomaterials (Nanda Subbarao)
    • Sterilization Case Study 1: Effects of Different Sterilization Techniques on Gold Nanoparticles (Ángela França, Beatriz Pelaz, María Moros, Christian Sánchez-Espinel, Andrea Hernández, Cristina Fernández-López, Valeria Grazú, Jesús M de la Fuente, Isabel Pastoriza-Santos and África González-Fernández)
    • Sterilization Case Study 2: Effects of Sterilization Techniques on Silver Nanoparticles (Jiwen Zheng, Jeffrey D Clogston, Anil K Patri, Scott E McNeil and Marina A Dobrovolskaia)
    • Surface Adsorbates on Nanomaterials and Their Possible Roles in Host Inflammatory and Toxicological Processing (Clinton F Jones, David G Castner and David W Grainger)
    • Endotoxin and Engineered Nanomaterials (Marina A Dobrovolskaia and Scott E McNeil)
    • Endotoxin Case Study: Interference of Nanoparticles with the Traditional Limulus Amebocyte Lysate Gel Clot Assay (Melanie Kucki, Christian Cavelius and Annette Kraegeloh)
    • Immunotoxicity Testing for Drug–Nanoparticle Conjugates: Regulatory Considerations (Simona Bancos, Katherine M Tyner and James L Weaver)
    • In Vitro Assays for Monitoring Nanoparticle Interaction with Components of the Immune System (Marina A Dobrovolskaia and Scott E McNeil)
    • Evaluating the Adverse Effects of Nanomaterials on the Immune System with Animal Models (Matthew J Smith, Colleen E McLoughlin, Kimber L White, Jr and Dori R Germolec)
    • Understanding the Correlation between in vitro and in vivo Immunotoxicity Tests for Engineered Nanomaterials (Marina A Dobrovolskaia and Scott E McNeil)
  • Volume 2: Haematocompatibility of Engineered Nanomaterials:
    • Nanoparticle Interaction with Plasma Proteins as It Relates to Biodistribution (Lennart Treuel and G Ulrich Nienhaus)
    • Protein Binding Case Study 1: Understanding Relationship between Protein Corona and Nanoparticle Toxicity (Marina A Dobrovolskaia, Barry W Neun, Sonny Man, Xiaoying Ye, Matthew Hansen, Anil K Patri, Rachael M Crist and Scott E McNeil)
    • Mathematical Modeling of the Protein Corona: Implications for Nanoparticulate Delivery Systems (Daniele Dell'Orco, Martin Lundqvist, Sara Linse and Tommy Cedervall)
    • Effects of Nanomaterials on Erythrocytes (Bridget Wildt, Richard A Malinauskas and Ronald P Brown)
    • The Effects of Engineered Nanomaterials on Cultured Endothelial Cells (Jan Simak)
    • The Effects of Engineered Nanomaterials on the Plasma Coagulation System (Jan Simak)
    • The Effects of Engineered Nanomaterials on Platelets (Jan Simak)
    • Nanoparticles and the Blood Coagulation System (Anna N Ilinskaya and Marina A Dobrovolskaia)
    • Complement Activation (Carolina Salvador-Morales and Robert B Sim)
    • Case Study: Complement Activation Related Hypersensitivity Reactions to PEGylated Liposomal Doxorubicin — Experimental and Clinical Evidence, Mechanisms and Approaches to Inhibition (Janos Szebeni, Franco Muggia and Yechezkel Barenholz)
    • Lymphatic System: A Prospective Area for Advanced Targeting of Particulate Drug Carriers (Indu Singh, Rajan Swami, Wahid Khan and Ramakrishna Sistla)
  • Volume 3: Engineered Nanomaterials and the Immune Cell Function:
    • Bidirectional Interaction between Nanoparticles and Carrier-Mediated Agents and Cells of the Mononuclear Phagocytic System (Sara K O'Neal, Andrew T Lucas, Whitney P Caron, Gina Song, John C Lay, and William C Zamboni)
    • Case Study: Application of LeukoLike Technology to Camouflage Nanoparticles from the Immune Recognition (Naama E Toledano Furman, Roberto Molinaro, Alessandro Parodi, Michael Evangelopoulos, Jonathan O Martinez, Claudia Corbo, Roberto Palomba, Iman K Yazdi and Ennio Tasciotti)
    • The Effects of Nanoparticles on Dendritic Cells (Valentyna Fesenkova)
    • The Effects of Nanoparticles on Bone Marrow Cells (Ekaterina Dadachova)
    • Nanoparticles, Immunomodulation and Vaccine Delivery (Sue D Xiang, Martina Fuchsberger, Tanya De L Karlson, Charles L Hardy, Cordelia Selomulya and Magdalena Plebanski)
    • Undesirable Adjuvanticity of Nanoparticles and Its Implication in Modulation of T Helper Responses (Ken-ichiro Inoue)
    • Immunosuppressive and Anti-Inflammatory Properties of Engineered Nanomaterials (A N Ilinskaya and M A Dobrovolskaia)
    • Nanoparticles as Drug Delivery Vehicels for the Therapy of Inflammatory Disorders (Deepthy Menon, J Gopikrishna, Dhanya Narayanan and Shantikumar V Nair)
    • Opportunities and Challenges in Nanotechnology-enabled Antiretroviral Delivery (Neill J Liptrott, Paul Curley, Lee M Tatham and Andrew Owen)
    • Nanostructures and Allergy (Silvia Lorenzo-Abalde and África González-Fernández)
    • Nanoparticles and Antigenicity (Marina A Dobrovolskaia)
    • Local Hyperthermia Treatment of Tumors Induces CD8+ T Cell-Mediated Resistance Against Distal and Secondary Tumors (Seiko Toraya-Brown, Mee Rie Sheen, Peisheng Zhang, Lei Chen, Jason R Baird, Eugene Demidenko, Mary Jo Turk, P Jack Hoopes, Jose R Conejo-Garcia and Steven Fiering)
Readership: Researchers, academics, undergraduates and graduates in toxicology, immunotoxicology and nanomedicine, and industry (small and mid biotech companies and big pharmaceutical companies), as well as regulatory agencies (EPA, FDA) and physicians.